Skip to main content

LCD L38737: Percutaneous Vertebral Augmentation (PVA) for Vertebral Compression Fracture (VCF)

LCD L38737, Percutaneous Vertebral Augmentation (PVA) for Vertebral Compression Fracture (VCF), is the Local Coverage Determination that Palmetto GBA applies to claims from 7 states (AL, GA, NC, SC, TN, VA, WV), effective 2025-11-20 and first in force 2021-11-28. The policy text runs 279 words, and its billing and coding article A58275 lists 13 ICD-10-CM codes that support medical necessity for 6 procedure codes. 4 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 13 covered ICD-10-CM codes: 5 more codes than L38201 (CGS Administrators, LLC, 8 codes, revised 2025-11-20) and 7 more codes than L34976 (First Coast Service Options, Inc., 6 codes, revised 2021-07-11).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Palmetto GBA
States and territories
7
AL GA NC SC TN VA WV
Revision effective
2025-11-20
Original effective
2021-11-28
Policy text
279 words
Covered ICD-10 codes (articles)
13

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L38737
ContractContractorTypeStates
11201Palmetto GBAA and B and HHH MACSC
11301Palmetto GBAA and B and HHH MACVA
11401Palmetto GBAA and B and HHH MACWV
11501Palmetto GBAA and B and HHH MACNC
11202Palmetto GBAA and B and HHH MACSC
11302Palmetto GBAA and B and HHH MACVA
11402Palmetto GBAA and B and HHH MACWV
11502Palmetto GBAA and B and HHH MACNC
10111Palmetto GBAA and B MACAL
10211Palmetto GBAA and B MACGA
10311Palmetto GBAA and B MACTN
10112Palmetto GBAA and B MACAL
10212Palmetto GBAA and B MACGA
10312Palmetto GBAA and B MACTN

Billing and coding article A58275: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A58275 (Billing and Coding: Percutaneous Vertebral Augmentation (PVA) for Vertebral Compression Fracture (VCF)) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A58275: Billing and Coding: Percutaneous Vertebral Augmentation (PVA) for Vertebral Compression Fracture (VCF) (Billing and Coding, effective 2022-08-21)

Covered ICD-10-CM codes
13
2 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
6
Full article
cms.gov record
First 13 covered ICD-10-CM codes in A58275
ICD-10-CMDescription (FY2027)
C41.2Malignant neoplasm of vertebral column
C79.51Secondary malignant neoplasm of bone
C90.00Multiple myeloma not having achieved remission
C90.02Multiple myeloma in relapse
M80.08XAAge-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture
M80.08XGAge-related osteoporosis with current pathological fracture, vertebra(e), subsequent encounter for fracture with delayed healing
M80.08XKAge-related osteoporosis with current pathological fracture, vertebra(e), subsequent encounter for fracture with nonunion
M80.08XPAge-related osteoporosis with current pathological fracture, vertebra(e), subsequent encounter for fracture with malunion
M80.08XSAge-related osteoporosis with current pathological fracture, vertebra(e), sequela
M80.88XAOther osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture
M80.88XSOther osteoporosis with current pathological fracture, vertebra(e), sequela
M84.58XAPathological fracture in neoplastic disease, other specified site, initial encounter for fracture
M84.58XSPathological fracture in neoplastic disease, other specified site, sequela

Procedure codes: 22510, 22511, 22512, 22513, 22514, 22515.

Coverage indications, limitations and medical necessity

PVA (percutaneous vertebroplasty (PVP) or percutaneous kyphoplasty (PKP)) is covered in patients who qualify based on the following criteria :

1. Inclusion criteria ( ALL are required ):

• Acute ( 1-3,10,25,27

• Symptomatic ( ONE ):

• Hospitalized with severe pain (Numeric Rating Scale (NRS) or Visual Analog Scale (VAS) pain score ≥8) 4-7

• Non-hospitalized with moderate-to-severe pain (NRS or VAS ≥5) despite optimal non-surgical management (NSM) 10 * ( ONE ):

• Worsening pain

• Stable-to-improved pain (but NRS or VAS still ≥5) ( with ≥ 2 of the following ):

• Progression of vertebral body height loss

• >25% vertebral body height reduction

• Kyphotic deformity

• Severe impact of VCF on daily functioning (Roland Morris Disability Questionnaire (RDQ) >17)

*Consider including pedicle periosteal infiltration 7

c. Continuum of care 10 (BOTH) :

• All patients presenting with VCF should be referred for evaluation of bone mineral density (BMD) and osteoporosis education for subsequent treatment as indicated.

• All patients with VCF should be instructed to take part in an osteoporosis prevention/treatment program.

2. Exclusion criteria 2,5,8-10 :

a. Absolute contraindication:

• Current back pain is not primarily due to the identified acute or subacute VCF(s)

• Osteomyelitis, discitis or active systemic or surgical site infection

• Pregnancy

b. Relative contraindication:

• Allergy to bone cement or opacification agents

• Uncorrected coagulopathy

• Spinal instability

• Myelopathy from the fracture

• Neurologic deficit

• Neural impingement

• Fracture retropulsion/canal compromise

• Greater than 3 vertebral fractures

Vertebral augmentation and kyphoplasty for VCFs with intractable spinal pain not relieved with medical therapy will be covered for osteolytic vertebral metastatic disease or myeloma involving a vertebral body.

Summary of evidence (opening)

Osteoporosis (and low bone mass) affects 50% of people over 50 years of age, or over 50 million people in the United States. Its primary impact, fractures (also called fragility or low-trauma fractures), occurs secondary to normal activity (e.g., bending, coughing, lifting, fall from a standing height), and eventually occurs in 50% of women and 20% of men. VCFs constitute one-quarter of osteoporotic fractures, 6 often at the midthoracic (T7-T8) and thoracolumbar junction (T12-L1). They may cause significant acute and chronic pain, leading to complications of impaired mobility (comparable to a hip fracture, pneumonia, loss of bone and muscle mass, incidental falls, deep venous thrombosis, depression, and isolation). 10 Medicare claims data shows an 85% 10-year mortality following a VCF diagnosis. 11 Under-diagnosis and under-treatment may exacerbate morbidity and mortality. 10 Vertebral augmentation provides a significant mortality benefit over nonsurgical management with a low number needed to treat (NNT).

Treatment options for symptomatic osteoporotic VCF range from NSM (anti-osteoporosis therapy, analgesics, limited activity/bed rest, back brace, physical therapy) to PVA (PVP and PKP). PVP involves the percutaneous injection of bone cement under image guidance into the VCF. PKP adds balloon tamponade within the fractured vertebral body to create a low-pressure cavity prior to cement injection. Both treatments aim to immobilize the fracture, reduce pain, and improve alignment.

Successful small European series introduced PVP into the United States in 1993; by 2007 encouraging preliminary observational data led to medical society endorsement and clinical acceptance in painful osteoporotic VCFs refractory to medical management. Subsequent early open-label randomized controlled trials (RCTs), including the Vertebroplasty for Painful Chronic Osteoporotic Vertebral Fractures (VERTOS) trial, 21 the Fracture Reduction Evaluation (FREE) trial, 22,23 VERTOS II, 14 and others, found a benefit of vertebral augmentation over NSM.

VERTOS II was a multicenter RCT that compared PVP and NSM of acute ( 14 Among 202 patients, the primary endpoint of pain relief at 1 month and 1 year was greater after PVP (-5.2/-5.7) than after NSM (-2.7/-3.7) (p 15 The authors acknowledged that despite the VERTOS II results, “clinicians still do not know how to best treat their patients,” but conclude that, pending further RCTs, PVP may be justified in patients with insufficient pain relief after 3 months of conservative treatment. 15

The contractor cites 38 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2021-11-28
Current revision effective
2025-11-20
Last reviewed by the contractor
2025-11-06
MCD version
19

Other related documents: A59138 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Palmetto GBA hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L38737 cover?

PVA (percutaneous vertebroplasty (PVP) or percutaneous kyphoplasty (PKP)) is covered in patients who qualify based on the following criteria : The full 279-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L38737 apply to?

Palmetto GBA applies it to Medicare claims in 7 states: AL, GA, NC, SC, TN, VA, WV. It binds only that contractor; 4 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L38737?

The companion billing and coding article A58275 lists 13 ICD-10-CM codes in 2 groups that support medical necessity; the first 13 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L38737?

A denial under LCD L38737 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A58275's 13 covered diagnosis codes, then file a redetermination with Palmetto GBA within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.